You are here: Industry Insights > Lilly

News List

Lilly files new class migraine drug with FDA pharmaphorum
December 05, 2018
Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition.
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer fiercepharma
November 19, 2018
Hutchison China MediTech’s Elunate, which recently became the first China-made drug to win a major oncology approval, has flopped in a key non-small cell lung cancer trial.
Lilly files lasmiditan for migraine pharmatimes
November 19, 2018
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for prevention of episodic cluster headache worldpharmanews
November 17, 2018
The NDA for lasmiditan includes data from two Phase 3 single-attack studies (SAMURAI and SPARTAN), which evaluated the safety and efficacy of lasmiditan for the acute treatment of migraine.
NextCure Raises $93 Million in Series B Financing firstwordpharma
November 14, 2018
BELTSVILLE, Md.--(BUSINESS WIRE)-- NextCure Inc., a privately-held biopharmaceutical company discovering and developing the next generation of immunomedicines for cancer
Lilly says diabetes drug Trulicity reduces heart risks in trial expressbpd
November 08, 2018
The company did not provide any details on the magnitude of risk reduction seen in the so-called outcomes trial
Lilly’s Trulicity shows superiority in reducing CV events in type 2 diabetes pharmaceutical-technology
November 07, 2018
Global pharmaceutical company Eli Lilly has announced its Trulicity (dulaglutide) has demonstrated superiority to placebo combined with standard of care in reducing the number of major adverse cardiovascular (CV) events (MACE) in patients with type 2 diab
Novo Nordisk expands job cuts to 1,300 as executives play down Lilly’s GLP-1 threat fiercepharma
November 02, 2018
Diabetes giant Novo Nordisk has been slimming down this year, and now we know just how much. First it was 400 R&D jobs, then about 250 positions in the U.S., and now the company says it will have cut about 1,300 employees by the end of 2018.
Lilly signs licensing and research deal with Dicerna Pharmaceuticals pharmaceutical-technology
October 31, 2018
Eli Lilly has entered a global licensing and research alliance with Dicerna Pharmaceuticals to identify, develop and commercialise potential therapies for cardio-metabolic conditions, neurodegeneration and pain.
Lilly, Dicerna Announce Global Licensing Agreement contractpharma
October 30, 2018
Lilly, Dicerna Announce Global Licensing Agreement

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page